Rebecca Olin

6PUBLICATIONS
58CO-AUTHORS
Gene and molecular therapyHaematological tumoursHaematologyCardiology (incl. cardiovascular diseases)Physiotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

|Aug 25, 2023
Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients.

Angela Lee, Corinne Badgley, Mimi Lo

|Jun 23, 2023
Lack of disease control remains a major barrier to transplant for older patients with AML.

Mark Y Jeng, Denice Kong, Raja Rajalingam

|Aug 17, 2021
Physically "fit" for allogeneic stem cell transplant?

Reena V Jayani, Rebecca L Olin

Pageof 1